All Cardiovascular disease articles
-
VideoThe holistic management of patients requiring anticoagulation
This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021 -
Independent professional body guideline
HEART UK Managing hyperlipidaemia and COVID-19
A summary of collated current evidence surrounding the safety of lipid-lowering medications in patients who have COVID-19
-
Working party guideline/algorithm
Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
-
NICE guideline
NICE FH guideline
Summary of NICE guidance on the identification and management of familial hypercholesterolaemia, which includes diagnostic criteria and when to refer.
-
SIGN guideline
SIGN cardiac arrhythmias guideline
Read the latest recommendations on the management of atrial fibrillation and ventricular arrhythmias in acute coronary syndrome, coronary heart disease, and left-ventricular dysfunction as well as arrhythmias associated with cardiac arrest and coronary artery bypass graft.
-
Working party guideline/algorithm
Stable peripheral arterial disease guideline
This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.
-
Working party guideline/algorithm
Stable coronary artery disease guideline
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
-
NICE guideline
NICE chronic heart failure guideline
This summary of the NICE heart failure guideline covers management and monitoring treatment. Includes algorithms on diagnosis and therapies.
-
SIGN guideline
SIGN stable angina guideline
This summary includes management algorithms for patients with suspected angina, and patients with a definite diagnosis of stable angina.
-
SIGN guideline
SIGN CVD guideline
This summary covers estimation of cardiovascular event risk, lifestyle interventions, and pharmacological therapy.
-
News
SIGN releases updated guidance on cardiovascular disease
The Scottish Intercollegiate Guidelines Network (SIGN) has published SIGN 149 Risk estimation and the prevention of cardiovascular disease and SIGN 150 Cardiac rehabilitation . SIGN 149 Risk estimation and the prevention of cardiovascular disease : It is estimated that in 2015 cardiovascular disease (CVD) caused more ...
-
NICE guideline
NICE CVD guideline
A concise summary of NICE's evidence-based clinical guideline on lipid modification for the prevention of cardiovascular disease.
-
SIGN guideline
SIGN antithrombotics guideline
A clear SIGN guideline summary exploring antiplatelet and anticoagulant agents and indications for their use, including cardiac and cerebrovascular disease.
-
Independent professional body guideline
JBS cardiovascular disease prevention guideline
A clear summary of JBS' recommendations on the prevention of cardiovascular disease. Includes an algorithm to help with risk assessment and management.
